Search Results - addiction

2 Results

Sort By:

Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction

This technology includes a chemical series, including the NCGC00538279 compound, that selectively activates the GHSR1a G-protein pathway for calcium mobilization while only partially activating the beta-arrestin-2 translocation pathway. The resulting chemical series may be therapeutically valuable for addictive disorders. Activation of the GHSR1a G-protein...

Published: 10/28/2024 | Inventor(s): Noel Southall, Marc Ferrer-Alegre, Daniel Jansen, Mark Henderson, Xin Hu, David Kim, Juan Marugan

Keywords(s): ADDICTION, Chemical, FOOD, Funtionally, Ghrelin, LIGAND, NCG00538279, Novel, RECEPTOR, SELECTIVE, treatment, VEXXXX, VGXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Neurology, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Research Materials

Phantasmidine, a Nicotinic Receptor Agonist for the Treatment of Addiction and Neurological Disorders

The inventors have isolated and characterized an alkaloid, phantasmidine, from the skin of the Ecuadoran poison frog E. anthonyi. Phantasmidine is selective for beta4-containing receptor subtypes, unlike many nicotinic receptor agonists currently in development, which target beta2-containing receptor subtypes. This selectivity makes phantasmidine...

Published: 10/28/2024 | Inventor(s): Richard Fitch

Keywords(s): ADDICTION, AGONIST, Alkaloid, Alzheimer disease 1, Alzheimer disease 3, Alzheimer disease 4, Alzheimer disease type 1, Alzheimer disease type 4, Alzheimer disease, familial, type 3, EPIBATIDINE, IBXXXX, IXXXXX, nAChR, NBXXXX, NC2XXX, NCXXXX, Neurological, neurological disease, nicotine, NICOTINIC, NXXXXX, Patent Category - Chemistry, Phantasmidine

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology, Application > Research Materials, Application > Diagnostics